Veracyte to Acquire HalioDx, Solidifying Global Leadership in Cancer Diagnostics     Learn More
Veracyte to Acquire HalioDx, Solidifying Global Leadership in Cancer Diagnostics     Learn More
Skip to content
Veracyte to Present at Upcoming Investor Conferences
<< Back
Jun 2, 2021

Veracyte to Present at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jun. 2, 2021-- Details of the Raymond James Human Health Innovation Conference have been corrected.

The updated release reads:

VERACYTE TO PRESENT AT UPCOMING INVESTOR CONFERENCES

Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, today announced that Marc Stapley, chief executive officer, and Bonnie Anderson, executive chairwoman, are scheduled to participate in two upcoming virtual investor conferences:

  • Goldman Sachs 42nd Annual Global Healthcare Conference
    Fireside chat on Wednesday, June 9, 2021, at 9:40 a.m. Eastern Time
  • Raymond James Human Health Innovation Conference
    Fireside chat on Wednesday, June 23, 2021, at 2:40 p.m. Eastern Time

Live audio webcasts of the company’s presentations will be available by visiting Veracyte’s website at http://investor.veracyte.com/events-presentations. Replays of the webcasts will be available for 90 days following the conclusion of each live presentation broadcast.

About Veracyte

Veracyte (Nasdaq: VCYT) is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company’s tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping and renal cancer tests are in development. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

Investor and Media Contact:
Tracy Morris
Vice President of Corporate Communications & Investor Relations
650-380-4413
tracy.morris@veracyte.com

Source: Veracyte, Inc.